ThirtyFiveBio

ThirtyFiveBio is an Oxford, UK biotechnology company founded in 2021 to develop first-in-class small-molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal diseases, including ulcerative colitis, inflammatory bowel disease, and digestive-tract cancers. The company was incubated by the M:M Bio (Molecule to Medicine) drug-discovery ecosystem together with Canaan Partners, and is backed by AbbVie Ventures, Mayewell Capital, and Innovate UK. It is a preclinical drug-discovery company with plans for first-in-human trials, not a software or API provider; this profile carries no developer API surface.

ThirtyFiveBio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Gastrointestinal.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsDrug DiscoveryGastrointestinalLife SciencesHealthcareTherapeutics

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/thirtyfivebio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website

Website

About

About

Source (apis.yml)

aid: thirtyfivebio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/thirtyfivebio.png
name: ThirtyFiveBio
description: ThirtyFiveBio is an Oxford, UK biotechnology company founded in 2021 to develop first-in-class small-molecule
  inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal diseases, including ulcerative
  colitis, inflammatory bowel disease, and digestive-tract cancers. The company was incubated by the M:M Bio (Molecule to
  Medicine) drug-discovery ecosystem together with Canaan Partners, and is backed by AbbVie Ventures, Mayewell Capital, and
  Innovate UK. It is a preclinical drug-discovery company with plans for first-in-human trials, not a software or API provider;
  this profile carries no developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/thirtyfivebio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Gastrointestinal
- Life Sciences
- Healthcare
- Therapeutics
apis: []
common:
- type: Website
  url: https://www.thirtyfivebio.com/
- type: About
  url: https://www.thirtyfivebio.com/about
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1